Release of podocalyxin into the extracellular space. Role of metalloproteinases

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 8, 2011, Pages 1504-1510

  Fernández, Darío ^b   Larrucea, Susana ^c   Nowakowski, Adam ^b   Pericacho, Miguel ^b   Parrilla, Roberto ^a,b   Ayuso, Matilde S ^a,b  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c HOSPITAL DE CRUCES   (Spain)

Author keywords

CHO cells; Extracellular podocalyxin; Fate of podocalyxin GFP; Human podocalyxin; Tera 1 cells

Indexed keywords

GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; METALLOPROTEINASE; PODOCALYXIN; PROTEIN KINASE C;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL MEMBRANE; ENZYME ACTIVATION; ENZYME ANALYSIS; EXTRACELLULAR SPACE; FILOPODIUM; GOLGI COMPLEX; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; DNA PRIMERS; EXTRACELLULAR SPACE; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASES; MICROSCOPY, ELECTRON, TRANSMISSION; PEPTIDE FRAGMENTS; PROTEIN KINASE C; RECOMBINANT FUSION PROTEINS; SIALOGLYCOPROTEINS; TETRADECANOYLPHORBOL ACETATE;

EID: 79959355048     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.05.009     Document Type: Article

References (31)

1. Nielsen J.S., Graves M.L., Chelliah S., Vogl A.W., Roskelley C.D., McNagny K.M. The CD34-related molecule podocalyxin is a potent inducer of microvillus formation. PLoS One 2007, 2:e237.
2. Kerjaschki D., Sharkey D.J., Farquhar M.G. Identification and characterization of podocalyxin-the major sialoprotein of the renal glomerular epithelial cell. J. Cell Biol. 1984, 98:1591-1596.
3. Seiler M.W., Rennke H.G., Venkatachalam M.A., Cotran R.S. Pathogenesis of polycation-induced alterations ("fusion") of glomerular epithelium. Lab. Invest. 1977, 36:48-61.
4. Kerosuo L., Juvonen E., Alitalo R., Gylling M., Kerjaschki D., Miettinen A. Podocalyxin in human haematopoietic cells. Br. J. Haematol. 2004, 124:809-818.
5. Kershaw D.B., Thomas P.E., Wharram B.L., Goyal M., Wiggins J.E., Whiteside C.I., Wiggins R.C. Molecular cloning, expression, and characterization of podocalyxin-like protein 1 from rabbit as a transmembrane protein of glomerular podocytes and vascular endothelium. J. Biol. Chem. 1995, 270:29439-29446.
6. Kershaw D.B., Beck S.G., Wharram B.L., Wiggins J.E., Goyal M., Thomas P.E., Wiggins R.C. Molecular cloning and characterization of human podocalyxin-like protein. Orthologous relationship to rabbit PCLP1 and rat podocalyxin. J. Biol. Chem. 1997, 272:15708-15714.
7. Schopperle W.M., Kershaw D.B., DeWolf W.C. Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin. Biochem. Biophys. Res. Commun. 2003, 300:285-290.
8. Casey G., Neville P.J., Liu X., Plummer S.J., Cicek M.S., Krumroy L.M., Curran A.P., McGreevy M.R., Catalona W.J., Klein E.A., Witte J.S. Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum. Mol. Genet. 2006, 15:735-741.
9. Somasiri A., Nielsen J.S., Makretsov N., McCoy M.L., Prentice L., Gilks C.B., Chia S.K., Gelmon K.A., Kershaw D.B., Huntsman D.G., McNagny K.M., Roskelley C.D. Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res. 2004, 64:5068-5073.
10. Larrucea S., Butta N., Arias-Salgado E.G., Alonso-Martin S., Ayuso M.S., Parrilla R. Expression of podocalyxin enhances the adherence, migration, and intercellular communication of cells. Exp. Cell Res. 2008, 314:2004-2015.
11. Arribas J., Borroto A. Protein ectodomain shedding. Chem. Rev. 2002, 102:4627-4638.
12. Rodriguez R.B., Butta N., Larrucea S., Alonso S., Parrilla R. Production and characterization of murine monoclonal antibodies against human podocalyxin. Tissue Antigens 2006, 68:407-417.
13. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
14. Bronson D.L., Fraley E.E., Fogh J., Kalter S.S. Induction of retrovirus particles in human testicular tumor (Tera-1) cell cultures: an electron microscopic study. J. Natl. Cancer Inst. 1979, 63:337-339.
15. Turk B.E., Huang L.L., Piro E.T., Cantley L.C. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat. Biotechnol. 2001, 19:661-667.
16. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
17. Amit T., Hochberg Z., Yogev-Falach M., Youdim M.B., Barkey R.J. Shedding of growth hormone-binding protein is inhibited by hydroxamic acid-based protease inhibitors: proposed mechanism of activation of growth hormone-binding protein secretase. J. Endocrinol. 2001, 169:397-407.
18. Arribas J., Coodly L., Vollmer P., Kishimoto T.K., Rose-John S., Massague J. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J. Biol. Chem. 1996, 271:11376-11382.
19. Mols J., Peeters-Joris C., Wattiez R., Agathos S.N., Schneider Y.J. Recombinant interferon-gamma secreted by Chinese hamster ovary-320 cells cultivated in suspension in protein-free media is protected against extracellular proteolysis by the expression of natural protease inhibitors and by the addition of plant protein hydrolysates to the culture medium. In Vitro Cell. Dev. Biol. Anim. 2005, 41:83-91.
20. Suojanen J., Salo T., Koivunen E., Sorsa T., Pirila E. A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth. Cancer Biol. Ther. 2009, 8:2362-2370.
21. van Kooten C., Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 2000, 67:2-17.
22. Sperandio M., Ley K. The physiology and pathophysiology of P-selectin. Mod. Asp. Immunobiol. 2005, 15:24-26.
23. Asakura M., Kitakaze M., Takashima S., Liao Y., Ishikura F., Yoshinaka T., Ohmoto H., Node K., Yoshino K., Ishiguro H., Asanuma H., Sanada S., Matsumura Y., Takeda H., Beppu S., Tada M., Hori M., Higashiyama S. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. 2002, 8:35-40.
24. van Mierlo G.J., Scherer H.U., Hameetman M., Morgan M.E., Flierman R., Huizinga T.W., Toes R.E. Cutting edge: TNFR-shedding by CD4+CD25+ regulatory T cells inhibits the induction of inflammatory mediators. J. Immunol. 2008, 180:2747-2751.
25. Rose-John S., Heinrich P.C. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 1994, 300(Pt 2):281-290.
26. Distler J.H., Jungel A., Huber L.C., Seemayer C.A., Reich C.F., Gay R.E., Michel B.A., Fontana A., Gay S., Pisetsky D.S., Distler O. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:2892-2897.
27. Ito T., Maki N., Hazeki O., Sasaki K., Nekooki M. Extracellular and transmembrane region of a podocalyxin-like protein 1 fragment identified from colon cancer cell lines. Cell Biol. Int. 2007, 31:1518-1524.
28. Hara M., Yanagihara T., Takada T., Itoh M., Adachi Y., Yoshizumi A., Kawasaki K., Yamamoto T., Kihara I. Podocalyxin on the glomerular epithelial cells is preserved well in various glomerular diseases. Nephron 1994, 67:123-124.
29. Hara M., Yanagihara T., Hirayama Y., Ogasawara S., Kurosawa H., Sekine S., Kihara I. Podocyte membrane vesicles in urine originate from tip vesiculation of podocyte microvilli. Hum. Pathol. 2010, 41:1265-1275.
30. Al-Nedawi K., Meehan B., Micallef J., Lhotak V., May L., Guha A., Rak J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 2008, 10:619-624.
31. Al-Nedawi K., Meehan B., Kerbel R.S., Allison A.C., Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3794-3799.